Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure

American Journal of Cardiology

Volumn 96, Issue 6, 2005, Pages 867-871

  Konstam, Marvin A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LOSARTAN; VALSARTAN;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; HEART FAILURE; HEART VENTRICLE REMODELING; HEART VENTRICLE VOLUME; HUMAN; META ANALYSIS; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 24944519319     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.05.037     Document Type: Note

References (46)

1. American Heart Association Heart Disease and Stroke Statistics - 2004 Update 2003 American Heart Association Dallas, Texas 22 23
2. M.A. Konstam, J.E. Udelson, I.S. Anand, J.N. Cohn Ventricular remodeling in heart failure a credible surrogate endpoint J Card Failure 9 2003 350 353
3. J.N. Cohn Remodeling as an end-point in heart failure therapy Cardiovasc Drugs Ther 18 2004 7 8
4. I.S. Anand, V.G. Florea, L. Fisher Surrogate endpoints in heart failure J Am Coll Cardiol 39 2002 1414 1421
5. V-HeFT VA Cooperative Studies Group J.N. Cohn, G.R. Johnson, R. Shabetai, H. Loeb, F. Tristani, T. Rector, R. Smith, R. Fletcher Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure Circulation 87 suppl 1993 V15 V16
6. M. Wong, G. Johnson, R. Shabetai, V. Hughes, G. Bhat, B. Lopez, J.N. Cohn Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure Veterans Affairs cooperative studies V-HeFT I and II Circulation 87 suppl 1993 V165 V170
7. R.S. Vasan, M.G. Larson, E.J. Benjamin, J.C. Evans, D. Levy Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction N Engl J Med 336 1997 1350 1355
8. S.A. Hunt, D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldman, G.S. Francis, T.G. Ganiats, S. Goldstein, G. Gregoratos, M.L. Jessup American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) Circulation 104 2001 2996 3007
9. J.N. Cohn, D.G. Archibald, S. Ziesche, J.A. Franciosa, W.E. Harston, F.E. Tristani, W.B. Dunkman, W. Jacobs, G.S. Francis, K.H. Flohr Effect of vasodilator therapy on mortality in chronic congestive heart failure results of a Veterans Administration cooperative study N Engl J Med 314 1986 1547 1552
10. G. Cintron, G. Johnson, G. Francis, F. Cobb, J.N. Cohn The V-HeFT VA Cooperative Studies Group Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure Circulation 87 suppl 1993 VI17 VI23
11. A.L. Taylor, S. Ziesche, C. Yancy, P. Carson, R. D'Agostino Jr, K. Ferdinand, M. Taylor, K. Adams, M. Sabolinski, M. Worcel African-American Heart Failure Trial Investigators Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N Engl J Med 351 2004 2049 2057
12. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
13. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
14. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 1992 685 691
15. J.N. Cohn, G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, R. Smith, W.B. Dunkman, H. Loeb, M. Wong A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N Engl J Med 325 1991 303 310
16. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
17. M. St. John Sutton, M.A. Pfeffer, T. Plappert, J.L. Rouleau, L.A. Moyé, G.R. Dagenais, G.A. Lamas, M. Klein, B. Sussex, S. Goldman Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction the protective effect of captopril Circulation 89 1994 68 75
18. M.A. Konstam, M.F. Rousseau, M.W. Kronenberg, J.E. Udelson, J. Melin, D. Stewart, N. Dolan, T.R. Edens, S. Ahn, D. Kinan SOLVD Investigators Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with heart failure Circulation 86 1992 431 438
19. M.A. Konstam, M.W. Kronenberg, M.F. Rousseau, J.E. Udelson, J. Melin, D. Stewart, N. Dolan, T.R. Edens, S. Ahn, D. Kinan SOLVD Investigators Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction Circulation 88 1993 2277 2283
20. B. Greenberg, M.A. Quinones, C. Koilpillai, M. Limacher, D. Shindler, C. Benedict, B. Shelton SOLVD Investigators Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction results of the SOLVD echocardiography substudy Circulation 91 1995 2573 2581
21. N. Sharpe, H. Smith, M. Murphy, S. Greaves, H. Hart, G. Gamble Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting enzyme inhibition Lancet 337 1991 872 876
22. B. Pitt, R. Segal, F.A. Martinez, G. Meurers, A.J. Cowley, I. Thomas, P.C. Deedwania, D.E. Ney, D.B. Snavely, P.I. Chang ELITE Study Investigators Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 349 1997 747 752
23. J.N. Cohn, G. Tognoni Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
24. B. Pitt, P.A. Poole-Wilson, R. Segal, F.A. Martinez, K. Dicksein, A.J. Camm, M.A. Konstam, G. Riegger, G.H. Klinger, J. Neaton ELITE II Investigators Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure randomised trial - the Losartan Heart Failure Survival Study ELITE II Lancet 355 2000 1582 1587
25. C.B. Granger, J.J.V. McMurray, S. Yusuf, P. Held, E.L. Michelson, B. Olofsson, J. Ostergren, M.A. Pfeffer, K. Swedberg CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors the CHARM-Alternative trial Lancet 362 2003 772 776
26. J.J.V. McMurray, J. östergren, K. Swedberg, C.V. Granger, P. Held, E.L. Michelson, B. Olofsson, S. Yusuf, M.A. Pfeffer CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors the CHARM-Added trial Lancet 362 2003 767 771
27. M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J.V. McMurray, E.L. Michelson, B. Olofsson, J. Ostergren, S. Yusuf, S. Pocock CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure the CHARM-Overall programme Lancet 362 2003 759 766
28. S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J.V. McMurray, E.L. Michelson, B. Olofsson, J. Ostergren CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction the CHARM-Preserved trial Lancet 362 2003 777 781
29. K. Dickstein, J. Kjekshus OPTIMAAL Steering Committee, for the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction the OPTIMAAL randomised trial Lancet 360 2002 752 760
30. M.A. Pfeffer, J.J.V. McMurray, E.J. Velazquez, J.-L. Rouleau, L. Køber, A.P. Maggioni, S.D. Solomon, K. Swedberg, F. Van de Werf, H. White Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
31. M.A. Konstam, R.D. Patten, I. Thomas, T. Ramahi, K. La Bresh, S. Goldman, W. Lewis, A. Gradman, K.S. Self, V. Bittner Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure results of the ELITE ventricular function substudy Am Heart J 139 2000 1081 1087
32. M. Wong, L. Staszewsky, R. Latini, S. Barlera, A. Volpi, Y.-T. Chiang, R.L. Benza, S.O. Gottlieb, T.D. Kleemann, F. Rosconi Val-HeFT Heart Failure Trial Investigators Valsartan benefits left ventricular structure and function in heart failure Val-HeFT echocardiographic study J Am Coll Cardiol 40 2002 970 975
33. A.P. Maggioni, I. Anand, S.O. Gottlieb, R. Latini, G. Tognoni, J.N. Cohn Val-HeFT Investigators Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors J Am Coll Cardiol 40 2002 1414 1421
34. M. Wong, L. Staszewsky, R. Latini, S. Barlera, R. Glazer, N. Aknay, A. Hester, I. Anand, J.N. Cohn Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure Valsartan Heart Failure Trial (Val-HeFT) echocardiographic data J Am Coll Cardiol 43 2004 2022 2027
35. M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, N.H. Shusterman US Carvedilol Heart Failure Study Group The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med 334 1996 1349 1355
36. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomized trial Lancet 353 1999 9 13
37. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
38. M. Packer, A.J. Coats, M.B. Fowler, H.A. Katus, H. Krum, P. Mohacsi, J.L. Rouleau, M. Tendera, A. Castaigne, E.B. Roecker Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
39. S.A. Hall, C.G. Cigarroa, L. Marcoux, R.C. Risser, P.A. Grayburn, E.J. Eichhorn Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade J Am Coll Cardiol 25 1995 1154 1161
40. R.N. Doughty, G.A. Whalley, G. Gamble, S. MacMahon, N. Sharpe Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group J Am Coll Cardiol 29 1997 1060 1066
41. RESOLVD Investigators Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy the randomized evaluation of strategies for left ventricular dysfunction pilot study Circulation 101 2000 378 384
42. T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure J Am Coll Cardiol 37 2001 1228 1233
43. M. Hayashi, T. Tsutamoto, A. Wada, T. Tsutsui, C. Ishii, K. Ohno, M. Fujii, A. Taniguchi, T. Hamatani, Y. Nozato Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction Circulation 107 2003 2559 2565
44. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
45. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, M. Gatlin Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
46. G.V. Antonopoulous, J. Lau, M.A. Konstam, J.E. Udelson Are drug-induced changes in left-ventricular ejection fraction or volume adequate surrogates for long-term natural history outcomes in heart failure? Circulation 100 suppl 1999 I-29